Safe and reproducible preparation of functional dendritic cells for immunotherapy in glioblastoma patients

Stem Cells Translational Medicine

Volumn 4, Issue 10, 2015, Pages 1164-1172

  Nava, Sara ^a   Lisini, Daniela ^a   Pogliani, Simona ^a   Dossena, Marta ^a   Bersano, Anna ^a   Pellegatta, Serena ^a   Parati, Eugenio ^a   Finocchiaro, Gaetano ^a   Frigerio, Simona ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Dendritic cells; Glioblastoma; Good manufacturing practices; Immunotherapy; Quality controls

Indexed keywords

DENDRITIC CELL VACCINE; ENDOTOXIN; CANCER VACCINE; TUMOR ANTIGEN; VACCINE;

ARTICLE; CELL MATURATION; CELL THERAPY; CELL VIABILITY ASSAY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG STERILITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MIXED LYMPHOCYTE REACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRAM EFFICACY; QUALITY CONTROL; UPREGULATION; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUE; CELL SURVIVAL; CRYOPRESERVATION; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; LIMULUS LYSATE TEST; MIXED LYMPHOCYTE CULTURE; MYCOPLASMA; PROCEDURES; REPRODUCIBILITY; TRANSLATIONAL RESEARCH; TRANSPLANTATION;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CLINICAL TRIALS, PHASE I AS TOPIC; CRYOPRESERVATION; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; LIMULUS TEST; LYMPHOCYTE CULTURE TEST, MIXED; MYCOPLASMA; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL MEDICAL RESEARCH; VACCINE POTENCY;

EID: 84942125465     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0091     Document Type: Article

References (27)

1. Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA 2000;97: 6242-6244.
2. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents. The Oncologist 2006;11:152-164.
3. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005;5:198-206.
4. Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol 2013;3:275.
5. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90:1115-1124.
6. Siesjö P, Visse E, Sjögren HO. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 1996;19:334-345.
7. Witham TF, Erff ML, Okada H et al. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 2002;50:1327-1334; discussion 1334-1335.
8. Pellegatta S, Poliani PL, Corno D et al. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006;28:527-531.
9. Heimberger AB, Crotty LE, Archer GE et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000;103:16-25.
10. Insug O, Ku G, Ertl HC et al. Adendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002;22(2A):613-621.
11. De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cellbased immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098-3104.
12. Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91: 1656-1662.
13. Wheeler CJ, Black KL. Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients. Curr Opin Mol Ther 2005;7: 35-47.
14. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-1179.
15. Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64: 4973-4979.
16. Council of Europe. European Pharmacopeia. 8th ed. Strasbourg, France: Council of Europe; 2014.
17. Nava S, Dossena M, Pogliani S et al. An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS One 2012;7: e52301.
18. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179: 1109-1118.
19. Bohnenkamp HR, Noll T. Development of a standardized protocol for reproducible generation of matured monocytederived dendritic cells suitable for clinical application. Cytotechnology 2003;42:121-131.
20. Babatz J, Röllig C, Oelschlägel U et al. Large-scale immunomagnetic selection of CD14+monocytes to generate dendritic cells for cancer immunotherapy: A phase I study. J Hematother Stem Cell Res 2003;12:515-523.
21. Eyrich M, Schreiber SC, Rachor J et al. Development and validation of a fully GMPcompliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy 2014;16:946-964.
22. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-1203.
23. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978;75: 5132-5136.
24. Dohnal AM, Graffi S, Witt V et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med 2009;13:125-135.
25. Berger TG, Strasser E, Smith R et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298: 61-72.
26. Sorg RV, Ozcan Z, Brefort T et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003;26:374-383.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.